ZA200108169B - Use of pegylated interferon alpha for renal cell carcinoma treatment. - Google Patents

Use of pegylated interferon alpha for renal cell carcinoma treatment. Download PDF

Info

Publication number
ZA200108169B
ZA200108169B ZA200108169A ZA200108169A ZA200108169B ZA 200108169 B ZA200108169 B ZA 200108169B ZA 200108169 A ZA200108169 A ZA 200108169A ZA 200108169 A ZA200108169 A ZA 200108169A ZA 200108169 B ZA200108169 B ZA 200108169B
Authority
ZA
South Africa
Prior art keywords
treatment
substance
composition
patient
pegylated interferon
Prior art date
Application number
ZA200108169A
Other languages
English (en)
Inventor
Esther Helen Rose
Mary Ellen Rybak
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA200108169B publication Critical patent/ZA200108169B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ZA200108169A 1999-04-08 2001-10-04 Use of pegylated interferon alpha for renal cell carcinoma treatment. ZA200108169B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28835999A 1999-04-08 1999-04-08

Publications (1)

Publication Number Publication Date
ZA200108169B true ZA200108169B (en) 2003-01-06

Family

ID=23106761

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200108169A ZA200108169B (en) 1999-04-08 2001-10-04 Use of pegylated interferon alpha for renal cell carcinoma treatment.

Country Status (23)

Country Link
EP (2) EP1043025B1 (cg-RX-API-DMAC7.html)
JP (2) JP4721488B2 (cg-RX-API-DMAC7.html)
CN (1) CN1367702A (cg-RX-API-DMAC7.html)
AR (1) AR029160A1 (cg-RX-API-DMAC7.html)
AT (2) ATE419002T1 (cg-RX-API-DMAC7.html)
AU (2) AU777406B2 (cg-RX-API-DMAC7.html)
BR (1) BR0009644A (cg-RX-API-DMAC7.html)
CA (1) CA2303752A1 (cg-RX-API-DMAC7.html)
CO (1) CO5170412A1 (cg-RX-API-DMAC7.html)
CY (1) CY1108919T1 (cg-RX-API-DMAC7.html)
DE (2) DE60041291D1 (cg-RX-API-DMAC7.html)
DK (2) DK1043025T3 (cg-RX-API-DMAC7.html)
ES (2) ES2239953T3 (cg-RX-API-DMAC7.html)
HU (1) HU230271B1 (cg-RX-API-DMAC7.html)
MX (1) MXPA00003401A (cg-RX-API-DMAC7.html)
MY (1) MY155221A (cg-RX-API-DMAC7.html)
NO (1) NO328983B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ514629A (cg-RX-API-DMAC7.html)
PE (1) PE20010026A1 (cg-RX-API-DMAC7.html)
PT (2) PT1535623E (cg-RX-API-DMAC7.html)
TW (2) TWI310314B (cg-RX-API-DMAC7.html)
WO (1) WO2000061174A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200108169B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR029160A1 (es) * 1999-04-08 2003-06-18 Schering Corp El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
US20070231301A1 (en) * 2006-03-31 2007-10-04 Warren Stephen L Parenteral low dose type 1 interferons for bladder cancer
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8053430B2 (en) 2008-10-06 2011-11-08 Haraldsson Boerje Treatment of renal cell carcinoma
EP2552443B1 (en) 2010-04-01 2021-07-14 Oncorena Ab Improved treatment of renal cell carcinoma
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法
KR102920712B1 (ko) 2017-05-24 2026-01-30 노파르티스 아게 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
WO2024186735A1 (en) * 2023-03-03 2024-09-12 Memorial Sloan-Kettering Cancer Center Methods and compositions for the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
CA2324467C (en) * 1998-03-26 2002-11-05 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
AR029160A1 (es) * 1999-04-08 2003-06-18 Schering Corp El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo

Also Published As

Publication number Publication date
HK1075417A1 (en) 2005-12-16
EP1535623A1 (en) 2005-06-01
PT1535623E (pt) 2009-03-19
MY155221A (en) 2015-09-30
NO328983B1 (no) 2010-07-05
TW200526243A (en) 2005-08-16
TWI310314B (en) 2009-06-01
JP3712914B2 (ja) 2005-11-02
DE60020442D1 (de) 2005-07-07
EP1043025A3 (en) 2000-12-20
HU230271B1 (hu) 2015-11-30
EP1535623B1 (en) 2008-12-31
JP2001288110A (ja) 2001-10-16
PE20010026A1 (es) 2001-02-05
ATE419002T1 (de) 2009-01-15
NZ514629A (en) 2004-02-27
CN1367702A (zh) 2002-09-04
PT1043025E (pt) 2005-09-30
DK1043025T3 (da) 2005-07-04
NO20014851D0 (no) 2001-10-05
MXPA00003401A (es) 2002-03-08
DE60020442T2 (de) 2006-05-04
ES2239953T3 (es) 2005-10-16
JP2000319196A (ja) 2000-11-21
BR0009644A (pt) 2002-01-08
CO5170412A1 (es) 2002-06-27
DK1535623T3 (da) 2009-04-27
WO2000061174A3 (en) 2001-01-25
HUP0200781A3 (en) 2002-09-30
AU2004242454A1 (en) 2005-01-20
WO2000061174A2 (en) 2000-10-19
DE60041291D1 (de) 2009-02-12
HUP0200781A2 (en) 2002-08-28
AU777406B2 (en) 2004-10-14
CY1108919T1 (el) 2014-07-02
CA2303752A1 (en) 2000-10-08
AR029160A1 (es) 2003-06-18
AU2004242454B2 (en) 2007-02-15
AU4204400A (en) 2000-11-14
EP1043025A2 (en) 2000-10-11
EP1043025B1 (en) 2005-06-01
ES2319777T3 (es) 2009-05-12
JP4721488B2 (ja) 2011-07-13
HK1032533A1 (en) 2001-07-27
ATE296638T1 (de) 2005-06-15
NO20014851L (no) 2001-12-07

Similar Documents

Publication Publication Date Title
US7482014B2 (en) Melanoma therapy
EP1043025B1 (en) Renal cell carcinoma treatment
US6605273B2 (en) Renal cell carcinoma treatment
JP2001288110A6 (ja) 腎細胞ガン処置
EP1043026B1 (en) Melanoma therapy
HK1075417B (en) Renal cell carcinoma treatment
HK1032533B (en) Renal cell carcinoma treatment
EP1043024B1 (en) Chronic myeloid leukemia (cml) therapy
HK1032349B (en) Melanoma therapy
HK1075416B (en) Melanoma therapy
HK1121409A (en) Melanoma therapy
HK1032348B (en) Chronic myeloid leukemia (cml) therapy